Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma

7 Jul 2022

Abstract excerpt

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed and treated in advanced tumor stages with poor prognosis. More effective screening programs and novel therapeutic means are urgently needed. Recent studies have regarded tight junction protein claudin 18.2 (CLDN18.2) as a candidate target for cancer treatment, and zolbetuximab (formerly known as IMAB362) has been developed against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Barrier Structure and Function Studies
Share to Caveolin-1 and cellular processes
Share to Cell Adhesion Molecules Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36051096
DOI: 10.4251/wjgo.v14.i7.1252

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinomaPMID 36051096Read ↗

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomesSemantic proximity Read ↗

Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapySemantic proximity Read ↗

Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Identification of CLDN18 as a potential diagnostic biomarker and therapeutic target for pancreatic cancer based on multiomic analysisSemantic proximity Read ↗

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. PishvaianSemantic proximity Read ↗

Prognostic significance of Claudin18.2 expression in patients with gastric cancer: Insights from original research and meta-analysisSemantic proximity Read ↗

TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinomaSemantic proximity Read ↗

KIF18B promotes the proliferation of pancreatic ductal adenocarcinoma via activating the expression of CDCA8Semantic proximity Read ↗

Claudin-1, A Double-Edged Sword in CancerSemantic proximity Read ↗

Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody DevelopmentSemantic proximity Read ↗

Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Oxysterol-Binding Protein 2 Promotes Pancreatic Ductal Adenocarcinoma Progression Through Epithelial-Mesenchymal Transition ProcessSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.